Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C

This report is the 5-year follow-up of those 25 UK patients with primary antibody deficiencies infected with hepatitis C virus (HCV), type la, from one batch of contaminated anti-HCV-screened intravenous immunoglobulin in 1993-1994, Of these patients, who were reported previously (1, 2), 2 cleared HCV spontaneously, 18 received early interferon-cu (IFN) treatment for 6 months, and 5 declined treatment or treatment was contraindicated, The clinical course of this cohort was followed prospectively using serial standardized questionnaires, Seven patients (54% of those who had completed therapy) had a sustained response (normal transaminase levels, negative serum HCV RNA) for 5 years posttreatment, Eight patients died: 3 from decompensated cirrhosis, 2 from pneumonia but with evidence of liver failure, and 3 from unrelated causes. One further patient developed decompensated cirrhosis but was successfully transplanted. Seven patients remain chronically infected; only 1 patient is symptomatic but 1 further patient has evidence of progressive fibrosis on liver histology, In conclusion, within 5 years, rapid end-stage HCV liver disease has been seen in 6/25 (24%) patients. Seven patients, (54% of those fully treated) remain well after treatment, making 9/25 (36% of the cohort) clear of virus after 5 years. Those who completed early treatment with IFN had a relatively high sustained response rate compared to previous studies in both immunodeficient and immunocompetent patients. (C) 2001 Academic Press.